Previous 10 | Next 10 |
2023-07-25 08:22:48 ET NeuroOne Medical Technologies Corporation ( NMTC ) -35% . announces pricing of public offering of common stock . Stoke Therapeutics ( STOK ) -34% announces positive new safety & efficacy data from patients treated with STK-001 in the ...
2023-07-20 10:23:14 ET Gainers: PainReform ( PRFX ) +55% . T2 Biosystems ( TTOO ) +19% . Inotiv ( NOTV ) +15% . Tarsus Pharmaceuticals ( TARS ) +14% . Nanobiotix ( NBTX ) +11% . Losers: Vir Biotechnology ( VIR ) ...
PARIS and CAMBRIDGE, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO — NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with ...
2023-07-19 08:33:57 ET 60 Degrees Pharmaceuticals ( NASDAQ: SXTP ) +34% . Hoth Therapeutics ( HOTH ) +23% r eceives Protocol Approval for HT-001 Cancer Therapeutic. Carvana ( CVNA ) +21% pares huge gain after filing to sell 35M shares. ...
2023-07-10 12:50:24 ET Gainers: Prestige Wealth ( PWM ) +39% . Nanobiotix S.A. ( NBTX ) +37% . Gorilla Technology Group ( GRRR ) +35% . NanoString Technologies ( NSTG ) +34% . Sientra ( SIEN ) +31% . T2 Biosystems ( TTOO ...
Nanobiotix S.A. (NASDAQ: NBTX) is one of today's top gainers. The company's shares are currently up 39.56% on the day to $7.02. Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile...
2023-07-10 06:01:03 ET Late-clinical stage biotechnology company, Nanobiotix ( NASDAQ: NBTX ) stock price surges 54% during pre-market hours as the company enters a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV. J...
PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
2023-06-06 03:29:54 ET Summary Nanobiotix is a clinical-stage biotechnology company focused on developing first-in-class product candidates using proprietary nanotechnology to transform cancer treatment. The company has one product candidate, NBTXR3, undergoing four clinical trial...
2023-06-01 10:07:16 ET Gainers: Nanobiotix ( NBTX ) +17% . Veeva Systems ( VEEV ) +13% . Biohaven ( BHVN ) +12% . Rockwell Medical ( RMTI ) +11% . Quipt Home Medical ( QIPT ) +9% . Losers: Lexicon Pharmaceuticals ( LXRX ...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...